

Meg J Jardine

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2471302/meg-j-jardine-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174
papers

9,135
citations

44
h-index

94
g-index

199
ext. papers

12,261
ext. citations

6.9
avg, IF

5.96
L-index

#	Paper	IF	Citations
174	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 ,	6.9	1
173	The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.. <i>Diabetes and Metabolism</i> , 2022 , 101331	5.4	0
172	Antiplatelet agents for chronic kidney disease.. <i>The Cochrane Library</i> , 2022 , 2, CD008834	5.2	1
171	Prior Cardiovascular Treatments-A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 834898	5.6	
170	A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 840611	5.4	
169	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 1888-1898	27.4	7
168	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022 , 2022, 1-12	3.9	
167	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021 , 52, 827-836	4.6	3
166	GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. <i>Kidney International</i> , 2021 ,	9.9	2
165	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1420-1425	6.7	2
164	Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. <i>Hemodialysis International</i> , 2021 , 25, 322	1.7	3
163	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021 , 233, 141-148	4.9	10
162	Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program. <i>Endocrinology, Diabetes and Metabolism</i> , 2021 , 4, e00247	2.7	1
161	Cloth Masks May Prevent Transmission of COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 580	8	
160	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1652-1659	6.7	3
159	Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis. <i>Kidney International Reports</i> , 2021 , 6, 1058-1065	4.1	1
158	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. <i>Circulation</i> , 2021 , 143, 1735-1749	16.7	19

157	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	7
156	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. <i>Stroke</i> , 2021 , 52, 1545-1556	6.7	11
155	129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial. <i>Diabetes</i> , 2021 , 70, 129-LB	0.9	
154	133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE. <i>Diabetes</i> , 2021 , 70, 133-LB	0.9	
153	131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial. <i>Diabetes</i> , 2021 , 70, 131-LB	0.9	
152	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021 , 324, 165-172	3.2	2
151	Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. <i>Nephrology</i> , 2021 , 26, 12-14	2.2	0
150	Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 382-390	6.7	20
149	The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 763-773	6.7	4
148	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 23-34.e1	7.4	12
147	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021 , 99, 999-1009	8.9	23
146	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021 , 99, 551-554	9.9	1
145	Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. <i>Kidney International Reports</i> , 2021 , 6, 284-295	4.1	3
144	SGLT2 inhibitors may offer benefit beyond diabetes. <i>Nature Reviews Nephrology</i> , 2021 , 17, 83-84	14.9	8
143	Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 252-257	6.7	2
142	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021 , 8, 1482-1493	3.7	4
141	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 384-395	6.9	12
140	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure: A Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1365-1375	6.9	1

139	Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2707-2715	6.7	0
138	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021 ,	9.5	22
137	Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. <i>Trials</i> , 2021 , 22, 573	2.8	1
136	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA _{1c} , disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021 , 64, 2402-2414	10.3	2
135	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
134	EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 215	15.1	2
133	The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1753-1766	6.7	8
132	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020 , 318, 126-129	3.2	6
131	No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial. <i>Nephrology</i> , 2020 , 25, 792-800	2.2	3
130	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 109-120	7.4	4
129	Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. <i>Diabetes Care</i> , 2020 , 43, 982-990	14.6	7
128	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1761-1769	4.3	1
127	A trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in Hemodialysis Patients: A Safety Device Study. <i>Blood Purification</i> , 2020 , 49, 468-478	3.1	21
126	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e014908	6	97
125	Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 1, 46-54	6.7	17
124	Examining outcomes in chronic disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. <i>JMIR Research Protocols</i> , 2020 , 9, e15646	2	5
123	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Diabetes</i> , 2020 , 69, 27-OR	0.9	1
122	1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial. <i>Diabetes</i> , 2020 , 69, 1098-P	0.9	

121	Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, i48-i55	4.3	9
120	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c. <i>Circulation</i> , 2020 , 141, 407-410	16.7	62
119	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 903-914	18.1	34
118	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2925-2936	12.7	30
117	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020 , 98, 849-859	9.9	19
116	Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1129-1138	6.9	1
115	Effects of Canagliflozin in Patients with Baseline eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1705-1714	6.9	30
114	Prevalence, incidence and risk factors of diabetes in Australian adults aged 45 years: A cohort study using linked routinely-collected data. <i>Journal of Clinical and Translational Endocrinology</i> , 2020 , 22, 100240	2.4	4
113	How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. <i>Kidney and Blood Pressure Research</i> , 2020 , 45, 823-836	3.1	
112	Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE. <i>Journal of Nephrology</i> , 2020 , 33, 977-983	4.8	2
111	Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks-A Narrative Review. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2204-2224	6.4	29
110	Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning. <i>Journal of Cardiac Failure</i> , 2020 , 26, 1028-1029	3.3	
109	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2653-2666	12.7	22
108	Therapy Escalation Following an Elevated HbA in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. <i>Diabetes Care</i> , 2020 , 43, e185-e187	14.6	1
107	Impact of supplemental private health insurance on dialysis and outcomes. <i>Internal Medicine Journal</i> , 2020 , 50, 542-549	1.6	2
106	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020 , 97, 42-61	9.9	106
105	Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis. <i>Journal of Cardiac Failure</i> , 2020 , 26, 482-491	3.3	7
104	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 845-854	18.1	335

103	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 96, 836-849	9.9	32
102	Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1823-1838	15.1	170
101	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1237-1250	6.7	114
100	Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. <i>BMJ Open</i> , 2019 , 9, e023736	3	3
99	Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 659-666	7.4	6
98	Cardiovascular adaptations associated with exercise in patients on hemodialysis. <i>Seminars in Dialysis</i> , 2019 , 32, 361-367	2.5	6
97	Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. <i>PLoS ONE</i> , 2019 , 14, e0213192	3.7	20
96	Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 87	2.3	5
95	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
94	The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. <i>Quality of Life Research</i> , 2019 , 28, 2081-2090	3.7	10
93	Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial. <i>Nephrology</i> , 2019 , 24, 1056-1063	2.2	8
92	Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis. <i>Nephrology</i> , 2019 , 24, 605-614	2.2	6
91	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , 2019 , 62, 1854-1867	10.3	29
90	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750	16.7	140
89	Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. <i>BMC Nephrology</i> , 2019 , 20, 258	2.7	3
88	Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis. <i>JAMA Internal Medicine</i> , 2019 , 179, 1316-1324	11.5	28
87	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019 , 191, E1128-E1135	3.5	13
86	1130-P: Temporal Trends in Pharmacotherapy for Diabetes. <i>Diabetes</i> , 2019 , 68, 1130-P	0.9	2

85	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2019 , 171, 181-189	8	44
84	Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review. <i>BMJ Global Health</i> , 2019 , 4, e001940	6.6	3
83	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2229-2242	12.7	57
82	Varying Association of Extended Hours Dialysis with Quality of Life. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1751-1762	6.9	5
81	Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. <i>Canadian Journal of Kidney Health and Disease</i> , 2019 , 6, 20543581-19894394	2.2	5
80	Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial. <i>Journal of Renal Nutrition</i> , 2019 , 29, 276-284	3	5
79	Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 332-343	7.4	45
78	Kidney Health Australia - Caring for Australasians with Renal Impairment guideline recommendations for infection control for haemodialysis units. <i>Nephrology</i> , 2019 , 24, 951-957	2.2	4
77	Effect of extended hours dialysis on sleep quality in a randomized trial. <i>Nephrology</i> , 2019 , 24, 430-437	2.2	5
76	Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 805-814	6.9	40
75	Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients. <i>BMC Nephrology</i> , 2018 , 19, 89	2.7	8
74	Cardiovascular Outcomes Reported in Hemodialysis Trials. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2802-2810	15.1	14
73	Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease. <i>Diabetes</i> , 2018 , 67, 258-OR	0.9	
72	Renal trials in diabetes need a platform: time for a global approach?. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 356-358	18.1	8
71	Glucose lowering and the kidney: are all drug classes equal?. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 835-837	18.1	
70	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018 , 138, 1537-1550	16.7	149
69	Muscle strength, mobility, quality of life and falls in patients on maintenance haemodialysis: A prospective study. <i>Nephrology</i> , 2017 , 22, 220-227	2.2	23
68	A Trial of Extending Hemodialysis Hours and Quality of Life. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1898-1911	12.7	42

67	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017 , 390, 1888-1917	40	419
66	Closing the gap between evidence and practice in chronic kidney disease. <i>Kidney International Supplements</i> , 2017 , 7, 114-121	6.3	8
65	Action plan for optimizing the design of clinical trials in chronic kidney disease. <i>Kidney International Supplements</i> , 2017 , 7, 138-144	6.3	12
64	Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0184398	3.7	21
63	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 432-442	27.4	214
62	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 368-375	12.7	220
61	Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units. <i>Hemodialysis International</i> , 2017 , 21, 213-223	1.7	8
60	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
59	Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. <i>BMJ, The</i> , 2016 , 355, i5599	5.9	19
58	Interventions for lowering plasma homocysteine levels in dialysis patients. <i>The Cochrane Library</i> , 2016 , CD004683	5.2	14
57	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2888-99	15.1	117
56	Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0159252	3.7	108
55	Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease: A systematic review and meta-analysis. <i>Nephrology</i> , 2016 , 21, 241-53	2.2	61
54	Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 289-94	6.7	18
53	Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. <i>The Cochrane Library</i> , 2016 , 4, CD009631	5.2	12
52	Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. <i>Nephrology</i> , 2015 , 20, 492-8	2.2	23
51	Renal effects of canagliflozin in type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015 , 31, 2219-31	2.5	42
50	A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 49-57	7.4	21

49	Interventions for lowering plasma homocysteine levels in kidney transplant recipients. <i>The Cochrane Library</i> , 2015 , CD007910	5.2	1
48	Design and participant baseline characteristics of SA Clinical Trial of Intensive DialysisS the ACTIVE Dialysis Study. <i>Nephrology</i> , 2015 , 20, 257-65	2.2	16
47	Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. <i>American Journal of Kidney Diseases</i> , 2014 , 63, 968-78	7.4	80
46	Angiotensin-converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. <i>Nephrology</i> , 2014 , 19, 617-22	2.2	16
45	Considerations of Nephrologists when Suggesting Dialysis in Elderly patients with Renal failure (CONSIDER): a discrete choice experiment. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 2302-9	4.3	19
44	Buttonhole cannulation and clinical outcomes in a home hemodialysis cohort and systematic review. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 110-9	6.9	61
43	Impact of estimated GFR reporting on late referral rates and practice patterns for end-stage kidney disease patients: a multilevel logistic regression analysis using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). <i>American Journal of Kidney Diseases</i> , 2014 , 64, 359-66	7.4	22
42	Acute Dialysis in Older Patients 2014 , 59-71		
41	Antiplatelet agents for chronic kidney disease 2013 ,		5
40	Non-tuberculous mycobacterial PD peritonitis in Australia. <i>International Urology and Nephrology</i> , 2013 , 45, 1423-8	2.3	29
39	Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2875-88	4.3	25
38	Comparative efficacy of a team-led treatment protocol for the management of renal anaemia. <i>Nephrology</i> , 2013 , 18, 649-54	2.2	1
37	Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013 , 34, 1807-17	9.5	124
36	Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 112-22	7.4	61
35	Effect of a vascular access surveillance program on service provision and access thrombosis. <i>Seminars in Dialysis</i> , 2013 , 26, 361-5	2.5	5
34	Outcomes of extended-hours hemodialysis performed predominantly at home. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 247-53	7.4	46
33	Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 515-30	7.4	33
32	Antiplatelet agents for chronic kidney disease. <i>Cochrane Database of Systematic Reviews</i> , 2013 , CD008834		49

31	mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 242-4	4.3	10
30	Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. <i>PLoS ONE</i> , 2013 , 8, e59055	3.7	15
29	Obstructive nephropathy secondary to a massive vesical calculus. <i>Internal Medicine Journal</i> , 2012 , 42, 471-2	1.6	
28	Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2012 , 156, 445-59	8	142
27	Prediction of kidney-related outcomes in patients with type 2 diabetes. <i>American Journal of Kidney Diseases</i> , 2012 , 60, 770-8	7.4	84
26	<i>Mycobacterium fortuitum</i> as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. <i>BMC Nephrology</i> , 2012 , 13, 35	2.7	6
25	If you can't comply with dialysis, how do you expect me to trust you with transplantation? Australian nephrologists' views on indigenous Australians' non-compliance and their suitability for kidney transplantation. <i>International Journal for Equity in Health</i> , 2012 , 11, 21	4.6	32
24	Effects of fibrates in kidney disease: a systematic review and meta-analysis. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2061-71	15.1	112
23	Survival of elderly dialysis patients is predicted by both patient and practice characteristics. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 3581-7	4.3	59
22	The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. <i>BMJ, The</i> , 2012 , 344, e3533	5.9	66
21	Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease 2012 ,		3
20	Benefits of exercise training in patients receiving haemodialysis: a systematic review and meta-analysis. <i>British Journal of Sports Medicine</i> , 2011 , 45, 1165-6	10.3	4
19	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2011 , 2, 265-78	4.9	19
18	Long-term cancer risk of immunosuppressive regimens after kidney transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 852-8	12.7	143
17	Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 956-65	15.1	127
16	Antiplatelet agents for chronic kidney disease 2010 ,		4
15	Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. <i>Annals of Internal Medicine</i> , 2010 , 153, 23-33	8	222
14	Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. <i>Annals of Internal Medicine</i> , 2009 , 151, 631-8	8	133

13	Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. <i>Kidney International</i> , 2009 , 76, 659-64	9.9	74
12	Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1813-21	12.7	640
11	Proteinuria and stroke: a meta-analysis of cohort studies. <i>American Journal of Kidney Diseases</i> , 2009 , 53, 417-25	7.4	102
10	Photopheresis therapy for problematic renal allograft rejection. <i>Journal of Clinical Apheresis</i> , 2009 , 24, 161-9	3.2	14
9	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009 , 373, 1009-15	40	302
8	Cyclosporine withdrawal improves long-term graft survival in renal transplantation. <i>Transplantation</i> , 2009 , 87, 1877-83	1.8	29
7	Interventions for lowering plasma homocysteine levels in kidney transplant recipients 2009 ,		1
6	Interventions for lowering plasma homocysteine levels in dialysis patients 2009 ,		2
5	Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. <i>Kidney International</i> , 2008 , 73, 963-70	9.9	25
4	The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2008 , 5, e207	11.6	148
3	Chemokine and toll-like receptor signaling in macrophage mediated islet xenograft rejection. <i>Xenotransplantation</i> , 2007 , 14, 48-59	2.8	19
2	Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 2766-72	12.7	83
1	Kidney Disease in Diabetes58-86		1